The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
First-in-human, phase 1a dose finding of LVGN6051 CD137/4-1BB agonistic antibody with or without pembrolizumab in patients with advanced solid tumors.
 
Adil Daud
Stock and Other Ownership Interests - Neuvogen; Trex bio
Honoraria - EMD Serono; Inovio Pharmaceuticals
Consulting or Advisory Role - Genoptix; GlaxoSmithKline; Merck; Merck; Oncosec; Pfizer
Research Funding - Bristol-Myers Squibb; Checkmate Pharmaceuticals; Checkmate Pharmaceuticals; Genentech/Roche (Inst); GlaxoSmithKline (Inst); Incyte; Merck/Schering Plough (Inst); Novartis; oncosec (Inst); Pfizer (Inst)
Patents, Royalties, Other Intellectual Property - patent relating to test for immunotherapy
 
Costantine Albany
No Relationships to Disclose
 
Vamsidhar Velcheti
Honoraria - ITeos Therapeutics
Consulting or Advisory Role - Amgen; AstraZeneca/MedImmune; Bristol-Myers Squibb; Elevation Oncology; GlaxoSmithKline; Merck; Merus; Taiho Oncology
Research Funding - Alkermes (Inst); Altor BioScience (Inst); Atreca (Inst); Bristol-Myers Squibb (Inst); Eisai (Inst); Genentech (Inst); Genoptix (Inst); GlaxoSmithKline (Inst); Heat Biologics (Inst); Leap Therapeutics (Inst); Merck (Inst); NantWorks (Inst); OncoPlex Diagnostics (Inst); RSIP Vision (Inst); Trovagene (Inst)
 
Ralph J. Hauke
Stock and Other Ownership Interests - Aethlon
Honoraria - Best Doctors, Inc
Research Funding - Amgen (Inst); Bristol-Myers Squibb (Inst); Exelixis (Inst); Merck (Inst); Novartis (Inst); Novartis (Inst); Novartis (Inst); Tizona Therapeutics, Inc. (Inst); US Oncology (Inst)
 
Jordi Rodon Ahnert
Consulting or Advisory Role - AADi; Avoro Capital Advisors; Boxer Capital; Chinese University of Hong Kong; Clarion Healthcare; Columbus Venture Partners; Cullgen; Debiopharm Group; Ellipses Pharma; Envision Pharma Group; iOnctura; Macrogenics; Merus; Monte Rosa Therapeutics; Monte Rosa Therapeutics; Oncology One; Pfizer; Sardona Therapeutics; Tang Advisors; Vall d'Hebron Institute of Oncology/Ministerio De Empleo Y Seguridad Social
Research Funding - AADi (Inst); Amgen (Inst); Bayer (Inst); Bicycle Therapeutics (Inst); BioAtla (Inst); BioMed Valley Discoveries (Inst); Black Diamond Therapeutics (Inst); Blueprint Medicines (Inst); Cellestia Biotech (Inst); Curis (Inst); CytomX Therapeutics (Inst); Deciphera (Inst); Fore Biotherapeutics (Inst); Genmab (Inst); GlaxoSmithKline (Inst); Hummingbird (Inst); Hutchison MediPharma (Inst); IDEAYA Biosciences (Inst); Kelun (Inst); Linnaeus Therapeutics (Inst); Loxo (Inst); Merck Sharp & Dohme (Inst); Merus (Inst); Mirati Therapeutics (Inst); Novartis (Inst); Nuvation Bio (Inst); Pfizer (Inst); Roche (Inst); Spectrum Pharmaceuticals (Inst); Symphogen (Inst); Taiho Pharmaceutical (Inst); Takeda/Millennium (Inst); Tango Therapeutics (Inst); Vall d'Hebron Institute of Oncology/Cancer Core Europe (Inst); Yingli Pharma (Inst)
Travel, Accommodations, Expenses - ESMO
Other Relationship - Vall d'Hebron Institute of Oncology/Ministerio De Empleo Y Seguridad Social
 
Daniel D. Karp
Research Funding - Phosplatin Therapeutics (Inst)
Travel, Accommodations, Expenses - Phosplatin Therapeutics
 
Apostolia Maria Tsimberidou
Consulting or Advisory Role - BioEclipse Therapeutics; BrYet; Diaccurate; Macrogenics; Nex-I; Vincerx Pharma
Research Funding - Agenus (Inst); BrYet; IMMATICS (Inst); Karus Therapeutics (Inst); Novocure (Inst); OBI Pharma (Inst); Parker Institute for Cancer Immunotherapy (Inst); Tempus (Inst); Tvardi Therapeutics (Inst)
 
Julia Wanda Cohen
Employment - Merck
Stock and Other Ownership Interests - Merck
 
Emmett V. Schmidt
Employment - Merck Sharp & Dohme
Stock and Other Ownership Interests - Merck Sharp & Dohme
Travel, Accommodations, Expenses - Merck Sharp & Dohme
 
Jieyi Wang
Employment - Lyvgen Biopharma
Leadership - Lyvgen Biopharma
Stock and Other Ownership Interests - Lyvgen Biopharma
Patents, Royalties, Other Intellectual Property - patents at Abbott, AbbVie, and Lyvgen
Travel, Accommodations, Expenses - Lyvgen Biopharma
 
C. Hubert Chan
Employment - Lyvgen Biopharma
Leadership - Lyvgen Biopharma
Stock and Other Ownership Interests - Lyvgen Biopharma
 
Siqing Fu
Research Funding - Abbisko (Inst); BeiGene (Inst); BioAtla (Inst); Boehringer Ingelheim (Inst); CUE Biopharma (Inst); Exelis (Inst); Exelis (Inst); Greenfire Bio (Inst); Hookipa Pharma (Inst); IMV (Inst); Innovent Biologics (Inst); K-Group Beta (Inst); Lilly (Inst); Lyvgen Biopharma (Inst); MacroGenics (Inst); MediLink Therapeutics (Inst); Millennium (Inst); Nerviano Medical Sciences (Inst); NeuPharma, Inc. (Inst); NextCure (Inst); NIH/NCI (Inst); Ningbo NewBay Medical Technology (Inst); Novartis (Inst); NovoCure (Inst); Nykode Therapeutics (Inst); Parexel International, LLC (Inst); Pionyr (Inst); PureTech (Inst); Sellas Life Sciences (Inst); Soricimed (Inst); SQZ Biotech (Inst); Sumitomo Dainippon Pharma Oncology (Inst); Taiho Oncology (Inst); Treadwell Therapeutics (Inst); Turnstone Bio (Inst); Tyligand Bioscience (Inst); Virogin Biotech (Inst)